

Amendments to the Claims:

Please amend claims 82 and 83 as indicated.

Claims 1-46 (Canceled).

47. (Previously Presented) The complex of claim 82 wherein the MHC class II molecules have the subtype DR B1 301 or DR B1 0401.

48. (Previously Presented) The complex of claim 82, wherein the MHC class II molecules are recombinant MHC class II molecules.

49. (Previously Presented) The complex of claim 82 wherein the peptide or peptide derivative is bound to a soluble peptide binding derivative of said MHC class II DR3 or DR4 molecules.

50. (Previously Presented) The complex of claim 82, wherein the complex carries a marker group.

51-54. (Canceled).

55. (Previously Presented) The complex of claim 82, wherein the peptide or peptide derivative carries a marker group.

56. (Previously Presented) A pharmaceutical composition, comprising a complex as claimed in claim 82, in combination with a pharmaceutically acceptable carrier.

57. (Previously presented) The pharmaceutical composition of claim 56, further comprising an accessory stimulating component.

58. (Previously presented) The pharmaceutical composition of claim 57, wherein the accessory stimulating component is a cytokine, surface antigen B7, or both.

59-81. (Canceled).

82. (Currently Amended) An isolated complex comprising a peptide or peptide derivative of glutamic acid decarboxylase which is bound to an allele or a peptide-binding derivative of MHC class II molecules DR3 or DR4 selected from the group consisting of DR B1 0301, DR B1 0401, DR B1 0402 and DR B1 0404,

wherein said peptide or peptide derivative is selected from the group consisting of SEQ ID NO:2, 3, 19-39 and a fragment thereof, and wherein said fragment has at least 6 contiguous amino acids of SEQ ID NO:2, 3 or 19-39.

83. (Currently Amended) An isolated complex comprising a peptide or peptide derivative of glutamic acid decarboxylase which is bound to an allele or a peptide-binding derivative of MHC class II molecules DR3 or DR4 selected from the group consisting of DR B1 0301, DR B1 0401, DR B1 0402 and DR B1 0404,

wherein said peptide or peptide derivative is at least 12 contiguous amino acids of SEQ ID NO:2, 3 or 19-39.